

Contra Costa Health Plan

Utilization Management.

Title: Diabetes Mellitus Clinical Guidelines: External Insulin Pumps and Continuous Glucose Monitoring Devices

Policy #: UM 15.073

Origin Date: 07/15/2024

Author: Irene Lo, MD, Chief Medical Officer

Reviewed and approved in UM Committee: 09/24

Reviewed and approved by Quality Council: 10/24

Applies to:

Medi-Cal

BHC

Regulatory/Accreditation:

X DMHC:

Other Reg. References:

Units:

Administration

Business Services

Marketing

Provider Affairs

Medicare

State Sponsored

X CMS:

X NCQA:

Advice Nurses

Case Management

Member Services

Quality Management

Commercial

X All

N/A

X DHCS:

N/A

X All Staff

Health Ed/Cultural Ling.

Planning, Survey, Reg Affairs

Auth/Utilization Management

PURPOSE

This policy addresses the use of insulin pumps and continuous glucose monitoring devices (CGMs, also referred to as continuous interstitial glucose monitoring devices) for the management of diabetes mellitus. Insulin pumps provide subcutaneous insulin infusion to treat diabetes mellitus. CGMs are devices that continuously measure glucose concentration in the interstitial space of the skin, allowing for indirect blood glucose measurements.

For members aged 21 years and over, this policy is to be used by the CCHP Authorizations/Utilization Management team when reviewing a treatment authorization request (TAR) for an external insulin infusion pump and/or a continuous glucose monitor (CGM). For members under the age of 21 who are eligible for California Children's Services (CCS), CCS guidelines should be utilized.

POLICY

EXTERNAL INSULIN PUMPS

External insulin pumps (either disposable or durable) are considered medically necessary when the following criteria are met:

- A. The individual has documented diabetes mellitus (any type); and
- B. The individual or caregiver(s) has completed a comprehensive diabetes education program; and
- C. Both of the following criteria are met:
 - a. Insulin injections are required multiple times daily; and
 - b. Multiple blood glucose tests are required daily, or a continuous glucose monitor is being used.

Refills for medically necessary disposable external insulin pumps are considered medically necessary.

Continued use of an external insulin pump (including for individuals who used a continuous insulin infusion pump prior to enrollment with CCHP) is considered medically necessary when the device has resulted in clinical benefit.

Replacement pumps: The replacement of external insulin pumps is considered medically necessary when the following criteria have been met:

- A. The device is out of warranty; and
- B. The device is malfunctioning; and
- C. The device cannot be refurbished.

The use of an external insulin pump is considered not medically necessary when the criteria above have not been met.

Continued use of an external insulin pump is considered not medically necessary when the criteria have not been met.

Replacement of insulin pumps is considered not medically necessary when the above criteria have not been met.

CONTINUOUS GLUCOSE MONITORING DEVICES (CGMs)

1. The member meets one of the following requirements:
 - a. Insulin-dependence; or
 - b. The member has claims history of regularly administered insulin in the past year; or
 - c. Documentation of regularly administered insulin use via chart notes, medical records, or additional clinical supportive documentation; or
 - d. The member is a new start, issued a new prescription, and will be using insulin administered on a continuing and regular basis.

-OR-

2. History of problematic hypoglycemia with documentation demonstrating recurrent (more than one) level 2 hypoglycemic events (glucose <54 mg/dl [3.0 mmol/L]) that persist despite attempts to adjust medication(s) and/or modify the diabetes treatment plan within the past year; or attestation from the provider the member has problematic hypoglycemic events.

-OR-

3. Pregnancy-Related Diabetes Diagnoses:
 - o Restricted to approval for the duration of the pregnancy and 12 months postpartum; and
 - o Estimated and/or actual date of delivery must be included on the request

A recent HbA1c value must be documented on the treatment authorization request, and the member's HbA1C value will be assessed as part of medical necessity